Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 11/20 | 0.62 |
| ▸ | LMNA | P02545 | 6/20 | 0.62 |
| ▸ | RAB9A | P51151 | 5/20 | 0.62 |
| ▸ | HPGD | P15428 | 3/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.62 |
| ▸ | RECQL | P46063 | 2/20 | 0.62 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.58 |
| ▸ | HTT | P42858 | 3/20 | 0.57 |
| ▸ | NPC1 | O15118 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.54 |
| ▸ | P4HB | P07237 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 3/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2162703 | 1.00 | MAPT (0.62) | MAPTLMNARAB9AHPGDCYP1A2 | |
| SCHEMBL23251385 | 0.85 | MAPT (0.81) | MAPTLMNARAB9AHPGDCYP1A2 | |
| SCHEMBL30440633 | 0.81 | MAPT (0.61) | MAPTLMNARAB9AHPGDCYP1A2 | |
| SCHEMBL99553 | 0.81 | MAPT (0.61) | MAPTLMNARAB9AHPGDCYP1A2 | |
| SCHEMBL31339149 | 0.81 | MAPT (0.61) | MAPTLMNARAB9AHPGDCYP1A2 | |
| SCHEMBL99552 | 0.81 | MAPT (0.61) | MAPTLMNARAB9AHPGDCYP1A2 | |
| SCHEMBL6758083 | 0.80 | P4HB (0.58) | MAPTLMNAHPGDALDH1A1HTT | |
| SCHEMBL12914243 | 0.78 | MAPT (0.70) | MAPTLMNARAB9AHPGDCYP1A2 | |
| SCHEMBL1186588 | 0.78 | MAPT (0.70) | MAPTLMNARAB9AHPGDCYP1A2 | |
| SCHEMBL7364598 | 0.78 | MAPT (0.70) | MAPTLMNARAB9AHPGDCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115874201-B | Electrosynthesis method of furanquinone | 南京工业大学 | 2025-02-25 | — | — | CN | disclosed |
| CN-116240560-A | Method for electrochemically synthesizing furoquinone by utilizing microchannel reactor | 南京工业大学 | 2023-06-09 | — | — | CN | disclosed |
| CN-115874201-A | Electric synthesis method of furan quinone | 南京工业大学 | 2023-03-31 | — | — | CN | disclosed |
| CN-108884047-B | Intermediates for the synthesis of aryl or heteroaryl substituted 5-hydroxy-1, 7-naphthyridine compounds and methods for their preparation | 沈阳三生制药有限责任公司 | 2022-03-08 | — | — | CN | disclosed |
| EP-3287456-B1 | COMPOUND OF 5-HYDROXYL-1,7-NAPHTHYRIDINE SUBSTITUTED BY ARYL OR HETEROARYL, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF | SHENYANG SUNSHINE PHARMACEUTICAL CO LTD (CN) | 2020-08-26 | — | — | EP | disclosed |
| US-9994566-B2 | Compound of 5-hydroxyl-1,7-naphthyridine substituted by aryl or heteroaryl, preparation method thereof and pharmaceutical use thereof | SHENYANG SUNSHINE PHARMACEUTICAL CO. LTD. (CN) | 2018-06-12 | — | — | US | disclosed |
| US-20180118738-A1 | COMPOUND OF 5-HYDROXYL-1,7-NAPHTHYRIDINE SUBSTITUTED BY ARYL OR HETEROARYL, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF | SHENYANG SUNSHINE PHARMACEUTICAL CO., LTD. (CN) | 2018-05-03 | — | — | US | disclosed |
| EP-3287456-A1 | COMPOUND OF 5-HYDROXYL-1,7-NAPHTHYRIDINE SUBSTITUTED BY ARYL OR HETEROARYL, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF | Shenyang Sunshine Pharmaceutical Co., Ltd. (CN) | 2018-02-28 | — | — | EP | disclosed |
| CN-106146491-B | The naphthyridine compounds of 5 hydroxyl 1,7, its preparation method and its pharmaceutical applications being optionally substituted aryl or heteroaryl | 沈阳三生制药有限责任公司 | 2017-12-12 | — | — | CN | disclosed |
| CN-106146491-A | 5-hydroxyl-1,7-naphthyridine compounds, its preparation method and the pharmaceutical applications thereof being optionally substituted aryl or heteroaryl | 沈阳三生制药有限责任公司 | 2016-11-23 | — | — | CN | disclosed |
| US-20040180914-A1 | 5-Cyano-2-aminopyrimidine derivatives | CELLTECH R&D LIMTIED | 2004-09-16 | — | — | US | disclosed |
| US-6579983-B1 | Potent and selective inhibitors of receptor tyrosine kinases involved in angiogenesis, especially KDR kinase and/or FGFr kinase | CELLTECH R&D LIMITED (GB) | 2003-06-17 | — | — | US | disclosed |
| EP-0862560-B1 | SUBSTITUTED 2-ANILINOPYRIMIDINES USEFUL AS PROTEIN KINASE INHIBITORS | CELLTECH THERAPEUTICS LTD (GB) | 2003-04-02 | — | — | EP | disclosed |
| US-20020147339-A1 | 5-cyano-2-aminopyrimidine derivatives | CELLTECH R&D LIMITED (GB) | 2002-10-10 | — | — | US | disclosed |
| EP-1187816-A1 | 5-CYANO-2-AMINOPYRIMIDINE DERIVATIVES | Celltech R&D Limited (GB) | 2002-03-20 | — | — | EP | disclosed |
| US-6235746-B1 | AUTOIMMUNE DISEASES; ANTIPROLIFERATIVE AGENT | CELLTECH THERAPEUTICS, LIMITED (GB) | 2001-05-22 | — | — | US | disclosed |
| WO-2000078731-A1 | 5-CYANO-2-AMINOPYRIMIDINE DERIVATIVES | CELLTECH R&D LIMITED (GB) | 2000-12-28 | — | — | WO | disclosed |
| US-5958935-A | Substituted 2-anilinopyrimidines useful as protein kinase inhibitors | CELLTECH THERAPEUTICS LIMITED (GB) | 1999-09-28 | — | — | US | disclosed |
| EP-0862560-A1 | SUBSTITUTED 2-ANILINOPYRIMIDINES USEFUL AS PROTEIN KINASE INHIBITORS | CELLTECH THERAPEUTICS LIMITED (GB) | 1998-09-09 | — | — | EP | disclosed |
| WO-1997019065-A1 | SUBSTITUTED 2-ANILINOPYRIMIDINES USEFUL AS PROTEIN KINASE INHIBITORS | CELLTECH THERAPEUTICS LIMITED (GB) | 1997-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118738-A1 | COMPOUND OF 5-HYDROXYL-1,7-NAPHTHYRIDINE SUBSTITUTED BY ARYL OR HETEROARYL, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF | HIF1AN, EGLN3, EGLN2 | MAPT 4811/4885LMNA 2841/4885RAB9A 1944/4885 |
| US-20040180914-A1 | 5-Cyano-2-aminopyrimidine derivatives | FLT1, FGFR1, KDR | MAPT 3073/4885LMNA 4343/4885RAB9A 3945/4885 |
| US-20020147339-A1 | 5-cyano-2-aminopyrimidine derivatives | FLT1, FGFR1, KDR | MAPT 3079/4885LMNA 4323/4885RAB9A 4037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.